AbD Serotec Expands Sales Office in D?ldorf to Support
(Thomson Reuters ONE) - MorphoSys AG / AbD Serotec Expands Sales Office in D?ldorf to Support processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. AbD Serotec to Increase Sales Activities in Europe and AsiaMorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that itsresearch and diagnostic antibodies unit AbD Serotec will expand its salesorganization in D?ldorf to support growth in continental and eastern Europeas well as in Asia. Today's official opening ceremony was performed by FriedrichG. Conzen, major of D?ldorf.Dr. Simon Moroney, Chief Executive Officer of MorphoSys Group, also attendedalong with Dieter Feger, Head of AbD Serotec. The expanded D?ldorf officewill coordinate global sales activities of AbD Serotec outside North, Centraland South America."While we expect demand in our traditional markets to remain solid, we haveidentified new areas of growth potential, and are now planning to expand oursales outreach to increase our market share in eastern Europe and Asia, as wellas in our core market here in western Europe." commented Dieter Feger, Head ofAbD Serotec. "Our plans to add a telemarketing sales force and expand our directmarketing efforts will act as central components of our growth strategy in thesemarkets."According to MorphoSys's financial guidance, AbD Serotec is expected tocontribute roughly one quarter of total group revenues in 2009, driven byabove-market growth rates, with an operating profit margin of up to 6%.MorphoSys expects the segment's financial performance to improve further in2010. More specific financial guidance for 2010 will be given at the Company'sfull year 2009 results presentation on February 25th, 2010.About MorphoSys:MorphoSys is an independent biotechnology company that develops novel antibodiesfor therapeutic, diagnostic and research applications. The Company's HuCALtechnology is one of the most powerful methods available for generating fullyhuman antibodies. By successfully applying this and other proprietarytechnologies, MorphoSys has become a leader in the field of therapeuticantibodies, one of the fastest-growing drug classes in human health-care.Through its alliances with some of the world's leading pharmaceutical companies,MorphoSys has created a pipeline of more than 60 drug candidates. The Company isexpanding its drug pipeline by adding new partnered programs, and by building aportfolio of fully-owned therapeutic antibodies. For its proprietary portfolio,the Company is focused on the areas of oncology and inflammation. Its mostadvanced program MOR103, a first-in-class, fully human antibody against GM-CSF,is currently tested in a Phase Ib/IIa trial in rheumatoid arthritis patients.Via its business unit AbD Serotec, MorphoSys is expanding the reach of itstechnologies in the diagnostics and research markets. MorphoSys is headquarteredin Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol"MOR". For further information, visit http://www.morphosys.com/HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®) and RapMAT(®) are registeredtrademarks of MorphoSys AGThis communication contains certain forward-looking statements concerning theMorphoSys group of companies. The forward-looking statements contained hereinrepresent the judgment of MorphoSys as of the date of this release and involverisks and uncertainties. Should actual conditions differ from the Company'sassumptions, actual results and actions may differ from those anticipated.MorphoSys does not intend to update any of these forward-looking statements asfar as the wording of the relevant press release is concerned.For more information, please contact:MorphoSys AGDr. Claudia Gutjahr-L?Head of Corporate Communications & IRTel: +49 (0) 89 / 899 27-122Mario BrkuljSenior Manager Corporate Communications & IRTel: +49 (0) 89 / 899 27-454Jessica KulpiSpecialist Corporate Communications & IRTel: +49 (0) 89 / 899 27-332investors(at)morphosys.com
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 09.02.2010 - 01:31 Uhr
Sprache: Deutsch
News-ID 1010120
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Martinsried / München
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 143 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"AbD Serotec Expands Sales Office in D?ldorf to Support
"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
